Form 8-K - Current report:
SEC Accession No. 0001104659-25-008863
Filing Date
2025-02-04
Accepted
2025-02-04 06:45:47
Documents
17
Period of Report
2025-02-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255059d1_8k.htm   iXBRL 8-K 39884
2 EXHIBIT 99.1 tm255059d1_ex99-1.htm EX-99.1 566939
3 EXHIBIT 99.2 tm255059d1_ex99-2.htm EX-99.2 594270
8 GRAPHIC tm255059d1_ex99-1img001.jpg GRAPHIC 3524
  Complete submission text file 0001104659-25-008863.txt   1525758

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20250204.xsd EX-101.SCH 4656
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20250204_def.xml EX-101.DEF 29175
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20250204_lab.xml EX-101.LAB 39689
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20250204_pre.xml EX-101.PRE 27659
19 EXTRACTED XBRL INSTANCE DOCUMENT tm255059d1_8k_htm.xml XML 11323
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 25585215
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)